American Society of Hematology

Figure 2.

Combined analysis of patients with R/R FL, MCL, or DLBCL who received blinatumomab doses of either <60 µg/m2per day or ≥60 µg/m2per day. Kaplan-Meier estimates for OS (A), PFS (B), and TFS (C).

Combined analysis of patients with R/R FL, MCL, or DLBCL who received blinatumomab doses of either <60 µg/m²per day or ≥60 µg/m²per day. Kaplan-Meier estimates for OS (A), PFS (B), and TFS (C).

This Feature Is Available To Subscribers Only